Total30 for Astigmatism Contact Lenses

Sponsor
Southern College of Optometry (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06052046
Collaborator
Alcon Research (Industry)
48
2
1
8.4
24
2.9

Study Details

Study Description

Brief Summary

Determine if Total30 for Astigmatism contact lenses (CLs) provide a comfortable wearing experience all day. CL discomfort affects most CL wearers with discomfort consistently topping the reasons why established CL wearers drop out of CLs. In fact, studies have consistently found that the frequency of CL dropout is around 20% with this dropout frequency staying relatively stable over the past 20 plus years. This static frequency of CL dropout is surprising since there have been a number of dramatic soft CL innovations during this time frame (e.g., widely available daily disposable CLs, silicone hydrogel CL materials with high oxygen transmissibility, new CL surface coatings).

Condition or Disease Intervention/Treatment Phase
  • Device: TOTAL30 for Astigmatism Contact Lenses
N/A

Detailed Description

A common issues that contact lens (CL) wearers frequently face is that their discomfort symptoms increase towards the end of the wear day. This burdensome discomfort can unfortunately cause patients to remove their CLs before their desired wear time. While comfortable wear times vary from patient to patient, Terry et al. has suggested that patients should be able to comfortably wear their CLs for at least 12 hours per day for at least 6 days per week. Nevertheless, the literature currently lacks sufficient data to comment fully on the full day wear experience, which for many patients may be 16 or more hours per day, especially if they have demanding careers. One CL that has the potential to allow for all day comfort is the Total30 for Astigmatism CLs, which is a new water gradient, monthly CL aimed at delivering all day comfort and visual performance. Thus, the purpose of this study is to map comfort over the full wear day in established, asymptomatic, soft CL wearers who are refit in Total30 for Astigmatism CLs. These data are not only important for judging the performance of Total30 for Astigmatism CLs, but they will provide some of the first insights into the full day CL wearing experience over one month.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
48 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
This prospective, one-month, three-visit study will refit all participants into TOTAL30 for Astigmatism Contact Lenses.This prospective, one-month, three-visit study will refit all participants into TOTAL30 for Astigmatism Contact Lenses.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
How Does Total30 for Astigmatism Perform During a Long Day of Wear?
Anticipated Study Start Date :
Sep 20, 2023
Anticipated Primary Completion Date :
May 11, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Total30 for Astigmatism Contact Lenses

TOTAL30 for Astigmatism Monthly Replacement Contact Lenses

Device: TOTAL30 for Astigmatism Contact Lenses
Participants will be refit into TOTAL30 for Astigmatism Contact Lenses and followed for 1 month.
Other Names:
  • Lehfilcon A
  • Outcome Measures

    Primary Outcome Measures

    1. Visual Analog Scale (VAS) Comfort Scores [Change from baseline at 1 month]

      A VAS will be used to compare end of day ocular comfort at about 16 hours of contact lens wear (± 50 scale with +50 being best possible comfort and -50 being worst possible comfort).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • 18- to 45-year-old

    • Visual acuity 20/20 or better

    • Contact Lens Dry Eye Questionnaire [CLDEQ]-8 scores <10

    • Willing to wear Total30 for Astigmatism CLs

    • Have a smart phone with text messaging capabilities

    • Astigmatism ranging from 0.75 D to 2.50 D in each eye

    • Regularly worn 2 week or monthly CLs within the past 6 months

    • Current CL wearer

    • Glasses prescription that is less than 2 years old

    • Willing to start wearing their CLs between 6:00 AM and 8:00 AM and wear their CLs until 11:00 PM each day text messaging data is collected

    Exclusion Criteria:
    • Current or past hard CL wearers

    • A known systemic health condition that is thought to alter tear film physiology

    • A history of viral eye disease

    • A history of ocular surgery

    • A history of severe ocular trauma

    • Have an active ocular infection or inflammation

    • Currently using isotretinoin-derivatives or ocular medications

    • Currently using rewetting drops or artificial tears

    • Pregnant or breast feeding

    • Willing to discontinue usage of current toric CLs one week prior to the initial visit

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Kannarr Eye Care Pittsburg Kansas United States 66762
    2 Coldwater VIsion Center Coldwater Mississippi United States 38618

    Sponsors and Collaborators

    • Southern College of Optometry
    • Alcon Research

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Southern College of Optometry
    ClinicalTrials.gov Identifier:
    NCT06052046
    Other Study ID Numbers:
    • IRB-00006733
    First Posted:
    Sep 25, 2023
    Last Update Posted:
    Sep 25, 2023
    Last Verified:
    Sep 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Southern College of Optometry
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 25, 2023